Read more about the article Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO

Today we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T™ therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about…

Continue ReadingToday we are announcing results from the ALPHA and ALPHA2 studies of our anti-CD19 AlloCAR T therapies in r/r non-Hodgkin lymphoma. Join us at 2:30PM PT/5:30PM ET to learn about the potential benefits of allogeneic cell therapy at our virtual CD19 Forum. $ALLO
Read more about the article This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.

This month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.— Allogene Therapeutics (@AllogeneTx)…

Continue ReadingThis month, as we celebrate the 3rd anniversary of Allogene, President and CEO David Chang M.D., PhD., reflects on the reasons to celebrate the last three years.